Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 9/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9750821 | 0.88 | CES1 (0.50) | CES1ESR1ESR2LMNAMAPT | |
| SCHEMBL9331729 | 0.88 | CES1 (0.50) | CES1ESR1ESR2LMNAMAPT | |
| SCHEMBL19056956 | 0.82 | CES1 (0.65) | CES1MLYCDTRPV1 | |
| Orthocresol SCHEMBL27487631 | 0.82 | CES1 (0.53) | CES1ESR1ESR2MLYCDCES2 | |
| SCHEMBL8486486 | 0.80 | CES1 (0.56) | CES1ESR1ESR2LMNAMLYCD | |
| SCHEMBL16823 | 0.80 | CES1 (0.62) | CES1MLYCDCA1CA2TRPV1 | |
| SCHEMBL1421656 | 0.80 | CES1 (0.70) | CES1HPGDMLYCDCA1CA2 | |
| SCHEMBL1851024 | 0.78 | CES1 (0.60) | CES1LMNAPKMMLYCDTRPV1 | |
| SCHEMBL7054999 | 0.78 | CES1 (0.60) | CES1MLYCDTRPV1 | |
| SCHEMBL1047383 | 0.78 | CA2 (0.67) | CES1LMNAPKMHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112331921-A | Lithium ion battery electrolyte flame-retardant additive and preparation method thereof | 谷建富 | 2021-02-05 | — | — | CN | claimed |
| US-6177417-B1 | HOST MATERIAL FOR ION SENSORS | Pyun, Hyung Jung (KR) | 2001-01-23 | — | — | US | claimed |
| CN-120535399-B | Preparation method of 4- (2, 2-trifluoro-1-alkoxyethyl) phenol | 上海麦克林生化科技股份有限公司 | 2026-03-24 | — | — | CN | disclosed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-120535399-A | Preparation method of 4- (2, 2-trifluoro-1-alkoxyethyl) phenol | 上海麦克林生化科技股份有限公司 | 2025-08-26 | — | — | CN | disclosed |
| EP-4347568-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | THE SCRIPPS RESEARCH INSTITUTE | 2024-03-21 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220397828-A1 | COMPOSITION CONTAINING A DICYANOSTYRYL GROUP, FOR FORMING A RESIST UNDERLAYER FILM CAPABLE OF BEING WET ETCHED | NISSAN CHEMICAL CORPORATION (JP) | 2022-12-15 | — | — | US | disclosed |
| WO-2022251533-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2006044707-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6177417-B1 | HOST MATERIAL FOR ION SENSORS | Pyun, Hyung Jung (KR) | 2001-01-23 | — | — | US | disclosed |
| CN-1263882-A | Method for preparing fluorine-substituted aromatic compound | MITSUI CHEMICALS INC (JP) | 2000-08-23 | — | — | CN | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
| US-5284838-A | Hypotensive agents | ELF SANOFI (FR) | 1994-02-08 | — | — | US | disclosed |
| US-5045229-A | Liquid crystals | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-09-03 | — | — | US | disclosed |
| EP-0296975-A1 | 2,2-Dimethyl-3-chromanol derivatives, process of their preparation and pharmaceutical compositions containing them | MERCK PATENT GmbH (DE) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | IAPP, GPR119, PNLIP | CES1 732/4885ESR1 2848/4885ESR2 837/4885 |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | XBP1, HSPA5, DNAJC10 | CES1 888/4885ESR1 162/4885ESR2 31/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | CES1 2029/4885ESR1 3890/4885ESR2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.